Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

LSX Virtual IPO Bootcamp

Summary

Speakers

Ariel White-Tsimikalis

Marishka DeToy

Related Content

Amgen and Sandoz Settle Denosumab BPCIA Litigation

Alexion’s Preliminary Injunction Motion Denied in Eculizumab BPCIA Litigation Against Samsung Bioepis

Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Orders

2nd BCLT Advanced Life Sciences Institute

IRA Litigation Updates: D.N.J. Rejects Challenges from BMS and Janssen; Four Cases Now on Appeal

Which Jobs More Frequently Require Non-Compete Agreements?

FDA Updates Draft Guidance on Promotional Communications of Prescription Biologics and Biosimilars

Accord BioPharma, Inc. Announces FDA Approval of HERCESSI (trastuzumab-strf)

Goodwin advises Templewater on Multiple Healthcare Acquisitions

Royalty Pharma To Acquire Royalty Interest In ImmuNext’s Frexalimab

BridgeBio Oncology Therapeutics Completes $200 Million Private Financing

Goodwin Bolsters Leading Life Sciences Practice with Partner Michael Siekman in Boston

Delphia Therapeutics Completes $67 Million Series A

Mariana Oncology To Be Acquired by Novartis For $1 Billion Upfront, And Up To $750 Million in Milestones

Deciphera Pharmaceuticals To Be Acquired By ONO Pharmaceutical For $2.4 Billion

Amid Continued Growth in the United Kingdom, Goodwin Relocates London Office to Iconic Paternoster Square

Life Sciences